RT Journal Article
T1 Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
A1 De Laurentiis, Michelino
A1 Borstnar, Simona
A1 Campone, Mario
A1 Warner, Ellen
A1 Bofill, Javier Salvador
A1 Jacot, William
A1 Dent, Susan
A1 Martin, Miguel
A1 Ring, Alistair
A1 Cottu, Paul
A1 Lu, Janice
A1 Ciruelos, Eva
A1 Azim, Hamdy A
A1 Chatterjee, Sanjoy
A1 Zhou, Katie
A1 Wu, Jiwen
A1 Menon-Singh, Lakshmi
A1 Zamagni, Claudio
K1 Advanced breast cancer
K1 CDK4/6 inhibitor
K1 Endocrine therapy
K1 Ribociclib
AB CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), the largest current trial of cyclin-dependent kinase 4 and 6 inhibitors in ABC. Patients treated with ≤ 1 line of prior chemotherapy and no prior endocrine therapy for ABC received ribociclib 600 mg/day (3-weeks-on/1-week-off) plus letrozole 2.5 mg/day and additionally monthly goserelin/leuprolide in men and pre-/perimenopausal women. Eligibility criteria allowed inclusion of patients with stable CNS metastases and an Eastern Cooperative Oncology Group performance status of 2. Primary objectives were safety and tolerability, and secondary objectives were efficacy and quality of life (QoL). Overall, 3,246 patients were evaluated (median follow-up 25.4 months). Rates of all-grade and grade ≥ 3 treatment-related adverse events (AEs) were 95.2% and 67.5%, respectively. Treatment-related discontinuations due to all grade and grade ≥ 3 AEs occurred in 12.9% and 7.3% of patients, respectively. Rates of all-grade AEs of special interest (AESI) were as follows: neutropenia (74.5%), increased alanine aminotransferase (16.2%), increased aspartate aminotransferase (14.1%), and QTcF prolongation (6.7%); corresponding values for grade ≥ 3 AESI were 57.2%, 7.7%, 5.7%, and 1.0%, respectively. Median time to progression was 27.1 months (95% confidence interval, 25.7 to not reached). Patient QoL was maintained during treatment. Safety and efficacy data in this expanded population were consistent with the MONALEESA-2 and MONALEESA-7 trials and support the use of ribociclib plus letrozole in the first-line setting for patients with HR + , HER2- ABC. linicalTrials.gov NCT02941926.
YR 2021
FD 2021-08-19
LK http://hdl.handle.net/10668/18396
UL http://hdl.handle.net/10668/18396
LA en
DS RISalud
RD Apr 10, 2025